

27 August 2019

NZX and Media Release

TRUSCREEN RESULTS OF ANNUAL SHAREHOLDING MEETING

The Truscreen Limited Annual Meeting of Shareholders was held on 27 August 2019.

Voting was conducted by poll of the shareholders present at the meeting and the proxies registered. Details of the resolutions and voting results were:

	Resolution	For	Against	Abstain/ Disregarded
1	Remuneration of auditor	145,165,692	10,000	168,179
2	Re-election of Mr Chris Horn as a director	144,161,882	953,810	228,179
3	Re-election of Mr Kelly Hickey as a director	145,115,692	0	228,179
4	Remuneration of non-executive directors	83,526,312	1,947,145	59,870,414
5	Ratification of prior issue of 7,142,856 shares	145,030,195	95,781	217,895
6	Ratification of prior issue of 9,677,363 shares	144,868,766	257,210	217,895
7	Ratification of prior issue of 9,677,363 options	144,468,766	657,210	217,895
8	Issue of placement shares and share options – Anthony Ho	144,605,525	558,747	179,599
9	Issue of up to 10,000,000 options to senior executives and directors	81,821,319	1,978,053	61,544,499

Guy Robertson

CFO

guyrobertson@truscreen.com

About TruScreen:

Watch our video on TruScreen: <http://truscreen.com/truscreen-the-company/truscreen-ultra-video/>

TruScreen is a Cervical Cancer Screening Device which offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world. TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.



TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with Pap tests including failed samples, poor patient follow up, patient discomfort and the need for supporting laboratory infrastructures. As such, TruScreen target market is developing countries where no large scale cervical cancer screening programs and infrastructure are in place, such as; China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is EC certified for use throughout Europe and CFDA approved for sale in China. Truscreen gained recognition from Global NGO's WHO and Unitaaid in a joint Cervical Cancer Technology Landscape released at the 72nd World Health Assembly.

For more information, visit our website at www.truscreen.com